These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26613680)

  • 1. Identification of a Japanese Lynch syndrome patient with large deletion in the 3' region of the EPCAM gene.
    Eguchi H; Kumamoto K; Suzuki O; Kohda M; Tada Y; Okazaki Y; Ishida H
    Jpn J Clin Oncol; 2016 Feb; 46(2):178-84. PubMed ID: 26613680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of rearrangements in Lynch syndrome cases associated with MSH2: characterization of a new deletion involving both EPCAM and the 5' part of MSH2.
    Pérez-Cabornero L; Infante Sanz M; Velasco Sampedro E; Lastra Aras E; Acedo Becares A; Miner Pino C; Durán Domínguez M
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1556-62. PubMed ID: 21791569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
    Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
    Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EPCAM germline and somatic rearrangements in Lynch syndrome: identification of a novel 3'EPCAM deletion.
    Spaepen M; Neven E; Sagaert X; De Hertogh G; Beert E; Wimmer K; Matthijs G; Legius E; Brems H
    Genes Chromosomes Cancer; 2013 Sep; 52(9):845-54. PubMed ID: 23801599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of EPCAM protein expression in diagnostics of Lynch syndrome.
    Kloor M; Voigt AY; Schackert HK; Schirmacher P; von Knebel Doeberitz M; Bläker H
    J Clin Oncol; 2011 Jan; 29(2):223-7. PubMed ID: 21115857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence and variability of germline EPCAM deletions in Lynch syndrome.
    Kuiper RP; Vissers LE; Venkatachalam R; Bodmer D; Hoenselaar E; Goossens M; Haufe A; Kamping E; Niessen RC; Hogervorst FB; Gille JJ; Redeker B; Tops CM; van Gijn ME; van den Ouweland AM; Rahner N; Steinke V; Kahl P; Holinski-Feder E; Morak M; Kloor M; Stemmler S; Betz B; Hutter P; Bunyan DJ; Syngal S; Culver JO; Graham T; Chan TL; Nagtegaal ID; van Krieken JH; Schackert HK; Hoogerbrugge N; van Kessel AG; Ligtenberg MJ
    Hum Mutat; 2011 Apr; 32(4):407-14. PubMed ID: 21309036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.
    Mur P; Pineda M; Romero A; Del Valle J; Borràs E; Canal A; Navarro M; Brunet J; Rueda D; Ramón Y Cajal T; Lázaro C; Caldés T; Blanco I; Soto JL; Capellá G
    Clin Genet; 2014 Mar; 85(3):260-6. PubMed ID: 23530899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of epithelial cell adhesion molecule expression in the algorithmic approach to Lynch syndrome identification.
    Musulen E; Blanco I; Carrato C; Fernandez-Figueras MT; Pineda M; Capella G; Ariza A
    Hum Pathol; 2013 Mar; 44(3):412-6. PubMed ID: 23026194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases.
    Rumilla K; Schowalter KV; Lindor NM; Thomas BC; Mensink KA; Gallinger S; Holter S; Newcomb PA; Potter JD; Jenkins MA; Hopper JL; Long TI; Weisenberger DJ; Haile RW; Casey G; Laird PW; Le Marchand L; Thibodeau SN
    J Mol Diagn; 2011 Jan; 13(1):93-9. PubMed ID: 21227399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors.
    Huth C; Kloor M; Voigt AY; Bozukova G; Evers C; Gaspar H; Tariverdian M; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Mod Pathol; 2012 Jun; 25(6):911-6. PubMed ID: 22388758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients.
    Guarinos C; Castillejo A; Barberá VM; Pérez-Carbonell L; Sánchez-Heras AB; Segura A; Guillén-Ponce C; Martínez-Cantó A; Castillejo MI; Egoavil CM; Jover R; Payá A; Alenda C; Soto JL
    J Mol Diagn; 2010 Nov; 12(6):765-70. PubMed ID: 20864635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1.
    Ligtenberg MJ; Kuiper RP; Chan TL; Goossens M; Hebeda KM; Voorendt M; Lee TY; Bodmer D; Hoenselaar E; Hendriks-Cornelissen SJ; Tsui WY; Kong CK; Brunner HG; van Kessel AG; Yuen ST; van Krieken JH; Leung SY; Hoogerbrugge N
    Nat Genet; 2009 Jan; 41(1):112-7. PubMed ID: 19098912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion.
    Lynch HT; Riegert-Johnson DL; Snyder C; Lynch JF; Hagenkord J; Boland CR; Rhees J; Thibodeau SN; Boardman LA; Davies J; Kuiper RP; Hoogerbrugge N; Ligtenberg MJ
    Am J Gastroenterol; 2011 Oct; 106(10):1829-36. PubMed ID: 21769135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients.
    Ligtenberg MJ; Kuiper RP; Geurts van Kessel A; Hoogerbrugge N
    Fam Cancer; 2013 Jun; 12(2):169-74. PubMed ID: 23264089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers.
    Kang SY; Park CK; Chang DK; Kim JW; Son HJ; Cho YB; Yun SH; Kim HC; Kwon M; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1568-78. PubMed ID: 25110875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.
    Kovacs ME; Papp J; Szentirmay Z; Otto S; Olah E
    Hum Mutat; 2009 Feb; 30(2):197-203. PubMed ID: 19177550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a better definition of EPCAM deletions in Lynch Syndrome: Report of new variants in Italy and the associated molecular phenotype.
    Cini G; Quaia M; Canzonieri V; Fornasarig M; Maestro R; Morabito A; D'Elia AV; Urso ED; Mammi I; Viel A
    Mol Genet Genomic Med; 2019 May; 7(5):e587. PubMed ID: 30916491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study.
    Kempers MJ; Kuiper RP; Ockeloen CW; Chappuis PO; Hutter P; Rahner N; Schackert HK; Steinke V; Holinski-Feder E; Morak M; Kloor M; Büttner R; Verwiel ET; van Krieken JH; Nagtegaal ID; Goossens M; van der Post RS; Niessen RC; Sijmons RH; Kluijt I; Hogervorst FB; Leter EM; Gille JJ; Aalfs CM; Redeker EJ; Hes FJ; Tops CM; van Nesselrooij BP; van Gijn ME; Gómez García EB; Eccles DM; Bunyan DJ; Syngal S; Stoffel EM; Culver JO; Palomares MR; Graham T; Velsher L; Papp J; Oláh E; Chan TL; Leung SY; van Kessel AG; Kiemeney LA; Hoogerbrugge N; Ligtenberg MJ
    Lancet Oncol; 2011 Jan; 12(1):49-55. PubMed ID: 21145788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alu in Lynch syndrome: a danger SINE?
    Hitchins MP; Burn J
    Cancer Prev Res (Phila); 2011 Oct; 4(10):1527-30. PubMed ID: 21972078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.